Viela Bio was a clinical-stage biotechnology company focused on severe inflammation and autoimmune diseases. Spun out of AstraZeneca in 2018, it developed Uplizna, an FDA-approved treatment for neuromyelitis optica spectrum disorder (NMOSD).
- In 2021, the company was acquired by Horizon Therapeutics for $3 billion.
- Horizon Therapeutics (HZNP) was acquired by Amgen in October 2023 for $27.8 billion.
History & Acquisition
- Founding: Launched in 2017 as a spinoff from AstraZeneca's MedImmune, led by CEO Bing Yao.
- Acquisition: In 2021, Horizon Therapeutics acquired Viela Bio in a $3 billion deal ( $53 per share). Horizon was subsequently acquired by Amgen in 2023.
- Legacy: The company was headquartered in Gaithersburg, Maryland.
Core Pipeline & Products
- Uplizna (inebilizumab-cdon): Viela Bio's flagship asset. It is a humanized monoclonal antibody targeting CD19, used to treat adults with NMOSD who are anti-AQP4 antibody-positive.
- Research Pipeline: Viela developed candidates for a range of autoimmune conditions, including myasthenia gravis, IgG4-related diseases, and systemic lupus erythematosus.
No comments:
Post a Comment